

2nd Symposium for Prinaity Immunodeficiencies, Paediatric Immunology 29-30 | 4 | 2010 - Aegii Zeppiou - ATHENS, GREECE

Autoinflammatory Diseases – Periodic Fever Syndromes Athens, April 30th 2010 Tim Niehues MD

Autoinflammatory Disease and Periodic Fever Syndromes

- Definitions
- Molecular Pathology and Classification
- Phenotype
- Challenges

Definition immune systems

- Adaptive immune system
 - Ability to adapt immunoglobulins and receptors postnatally by somatic mutation and gene rearrangement: Highly diverse repertoire and memory
 - Dysregulation: Autoantibodies/Autoreactive T cells

· Innate immune system

- Inherited receptors on phagocytes, NK cells, complement
- Phylogenetically ancient, hardwired, rapid-response system distinct from but, in mammals, intertwined with adaptive immunity
- Dysregulation: Autoinflammation

Definition Autoinflammatory disease

is characterised by

• both mendelian and complex genetic variants of the innate immune system without high titer autoantibodies or antigen specific T cells

· seemingly unprovoked episodes of inflammation

Periodic Fever Syndromes

are characterised by

- self-limitig recurrent fever episodes
- symptomfree interval
- multisystemic Inflammation
- · increased inflammatory parameters
- no infectuous agent

Provisional molecular/functional classification (Masters, 2009)

Type 1: Inflammasomopathies including Periodic Fever Syndromes

Type 2: NF- **K** B activation disorders

- Crohn's disease - NOD2 (16p12), ATG16L1, IRGM
- Blau syndrome, FCAS2 (Guadaloupe periodic fever)
- NOD2, NLRP12 (NALP12)
- Type 3: Protein folding disorders of the innate immune system
- TRAPSq
- TNFRSF1A (TNFR1, p55, CD120a)
- Type 4-6: Disorders of Complement, cytokine signalling, Macrophage activation
- Atypical HUS, Cherubism, Familial HLH

Unclassified

PFAPA, systemic onset Juvenile Idiopathic Arthritis









Pattern recognition receptors

- TLRs = Toll like receptors
- RLRs = Retinoid acid-inducible gene I (RIG-I)-like receptors
- NLRs =nucleotide-binding oligomerization domain (NOD)-like receptors
- DNA sensors, DAI (DNA-dependent activator of IFNregulatory factors)





Inflammasomes

• Macromolecular complexes, that sense various microbial products and endogenous "danger signals" to activate caspase-1, thereby initiating IL-1 β and IL-18 processing



Inflammasomopathies

- · Well-established autoinflammatory diseases
- caused by activating, gain-of-function mutations e.g in NLRP3 (originally denoted CIAS1 for <u>cold-induced</u> <u>autoinflammatory syndrome 1)</u>
- The NLRP3 inflammasome interacts with proteins mutated in other autoinflammatory diseases
 - Pyrin in FMF

Autoinflammatory Disease and Periodic Fever Syndromes

- Definitions
- Molecular Pathology and Classification
- Phenotype
- Challenges

Georgios, 2 month-old

- From birth on continuous fever episodes
- Drug history: Many antibiotics, Fluconazole
- Urticaria in changing locations
- Leucocytes: 20.000-40000.
 Elevated inflammation markers (e.g. CRP)





Georgios, 3 month-old

- · No effect of antibiotics
- Steroid dependent

> Anakinra (IL1 Receptor antagonist)

- Fever and inflammation gone for good
- Mutation in NLPR3















DIRA: Deficiency of IL-1 receptor antagonist



- · pustular rash on the neck, arm, and trunk
- heterotopic bone formation and periosteal elevationon the proximal femurs bilaterally (red arrows).
- pathognomonic widening of multiple anterior ribs in a neonate (red arrowheads)
- No CNS involvement (as opposed to CINCA)

Familial Mediterranean Fever (FMF) •Pyrin (= TRIM20) part of a larger family termed the TRIpartite Motif (TRIM) proteins loss of function mutations with recessively inherited disease ?? >Antiinflammatory effect of wild-type pyrin gain-of-function mutations with dominantly inherited disease ??

>proinflammatory role of wild-type pyrin









Nicolai, 10 years

- Since newborn age 40-41° C in weekly to monthly intervals (every 2-12 weeks); duration 3-5 days
- Pharyngitis, feinfleckiges Exanthem an Armen, Oberschenkel, Füßen, Fußschlen und im Gesicht, Kopf-, Bauchschmerzen, Myalgien und Arthralgien
- · Leucocytosis, raised ESR, CRP



Nicolai

IgD 665 mg/dl = 475 U/ml (Normal <100 U/ml)

•<u>Mevalonic acid in urine:</u> 0,8 mmol/mol Creatinine (Normal <0,29 mmol/mol)

Homozygous mutation Valin $_{\rm 377}$ \rightarrow Isoleucin in Exon 11 of the Mevalonatkinase gene MVK









TRAPS (<u>TNF</u> receptor <u>associated</u> periodic <u>syndome</u>)

- Dominantly inherited heterozygous missense mutations, gain of function?
- Shedding hypothesis unlikely

Mutations cause

- TNFR1 to aggregate
- inhibit TNFR1 trafficking to the cell membrane
- JNK activation





TRAPS

- Painful Erythemas
- Conjunctivitis, periorbital edema 80%

•Migratorischy exanthemas 60%

Colicky abdominal pain



Summary I

- Severe enough to cause illness, but not so severe as to be embryonic lethal
- NLR proteins monitor homeostatic pathways that can be perturbed by individual PAMPs or DAMPs to trigger activity of the inflammasome.
- IL-1 β occupies a special place
 - unique in the ability to trigger innate immunity without major provocation of the adaptive immune system
 - blockade highly successful

Summary II

Clinical clues

- Cryopyrinopathies (MWS, CINCA): urticaria-like rash, deafness, blindness
- FMF: Erysipelas like erythema
- Hyper IgD/Mevalonate Kinase deficiency: early age, Lymphadenopathy, Splenomegaly
- TRAPS: long attacks >1week, periorbital edema, conjunctivitis

Treatment	Clinical studios (adults/childron)	No. of patient
Hereditary fever disorders		no. or pations
FMF	Colchicine-controlled trials adults ⁸⁻¹⁰	>100
	Colchicine open-label trials, dutits	>100
	Anakinra case reports both ²⁰⁻²⁵	<10
	Rilonacent trial in progress	
TRAPS	Etanercent small trials, both ^{7,13}	>10
	Anakinra case reports both ^{14,29,30}	<10
Hyper-IgD syndrome with periodic fever	Anakinra case reports, both ²⁶⁻²⁸	<10
CAPS	Tinanina ease reports, com	
FCAS	Anakinra open-label trials, both ^{16,17}	>10
	Rilonacept controlled trials, both18	<100
	Canakinumab controlled trials, both ¹⁹	<100
MWS	Anakinra open-label trials, both ¹⁶	>10
	Rilonacept controlled trials, both18	<10
	Canakinumab controlled trials, both19	>10
NOMID	Anakinra open-label trial, children15	>10
	Canakinumab trials in progress	



To be explored

- The underlying genetic basis and pathophysiologic mechanisms for many inherited autoinflammatory syndromes
- Specific mechanisms underlying the activation of the inflammasome
- The long-term efficacy and safety of IL-1-targeted therapies
- The role of novel upstream and downstream inflammasome-targeted therapies in the future



Excellent Reviews • Goldbach-Mansky, JACI 2009 • Hoffman, JACI 2009 • Morgensen, Microbiology Reviews 2009 • Masters, Ann. Rev. Immunol., 2009 • Rigante, Europ. Rev. Med. Pharmacolog. Sc., 2010







Innate immune system and Autoimmunity: seperate?

- association of NLRP1 with vitiligo, and a range of other autoimmune diseases
- NLRP1 is highly expressed in T cells,
- Allogeneic stem cell transplantation, recipient variants in *NLRP1*, as well as donor variants at *NLRP2* and *NLRP3*, have been shown to be important prognostic factors
- Variants at another NLR gene NOD2/CARD15, in both donor and recipient are associated with graft-versus-host disease and mortality



Jric acio CPPE sbesto silico Extrinsic recurrent arthritis, sterile but purulent synovial fluid, pyoderma gangrenosum (large,open purulent lesions) severe cystic acne dominantly inherited • mutations of CD2-binding protein 1 (CD2BP1) = olL-16 proline serine threonine phosphatase-interacting protein 1 (PSTPIP1), IL-1β Extr

<u>Pyogene sterile A</u>rthritis, <u>Pyoderma gangrenosum, Akne</u>

- recurrent arthritis, sterile but purulent synovial fluid,
- pyoderma gangrenosum (large,open purulent lesions)
- severe cystic acne
- dominantly inherited mutations of CD2-binding protein 1 (CD2BP1) = proline serine threonine phosphatase-interacting protein 1 (PSTPIP1),

